Panorama NIPT: Understanding Non-Invasive Prenatal Genetic Screening
DetailsPanorama™
Non-invasive prenatal screening (NIPT)
Panorama™ is a blood-based genetic, prenatal screening test of the pregnant person that screens for common chromosomal conditions that affect a baby’s health. Panorama™ uses SNP*-based technology to deliver highly accurate results and unique insights for both singleton and twin pregnancies.
Panorama™ can be performed as early as nine weeks gestation. Most results will be returned to your doctor within 10 working days from the date that samples are received.
Panorama™ is a screening test, which means that this test does not make a final diagnosis. A high risk result means that your pregnancy has a higher chance of having a specific genetic condition. However, you cannot know for sure if your baby has that condition based upon the screening result alone. The test does NOT tell with certainty if a fetus is affected, and only tests for the conditions ordered by the healthcare provider. High risk test results need diagnostic confirmation by alternative testing methods. All medical decisions should be made after discussion with your healthcare provider regarding diagnostic testing during the pregnancy, like chorionic villus sampling (CVS) or amniocentesis, or testing the baby after birth.
Early insight for a confident pregnancy
Every pregnancy is unique and brings its own questions. Panorama™ NIPT lets you learn about your baby's chromosomal health in the early weeks of pregnancy, from a single blood sample taken from the mother.
You review the result together with your doctor, so that the next steps can be planned with confidence.
Backed by evidence
Years of clinical experience and published research underpin confidence in the Panorama™ test.
-
Experience
10 years
in clinical use
-
Scientific publications
40+
peer-reviewed
-
Patients
2 million+
included in published studies
Source: Magnoliei 71, București
The Panorama™ difference
- The only SNP-based NIPT, designed to inform decisions during pivotal moments of pregnancy care.
- A differentiated, highly-accurate screening approach evaluates SNPs – the 1% of our DNA that makes us different from one another – to screen for common trisomies, aneuploidies and microdeletions.
- A sequencing platform of >13K SNPs enables Panorama™ to deliver a curated prenatal cfDNA screening test that accounts for all ethnicities and population variability.
Validated with clinical rigor
SMART
SNP-based Microdeletion and Aneuploidy RegisTry
SMART, the largest prospective NIPT study, evaluated the performance of SNP-based NIPT in a real-world population. All results included in the analysis were validated with genetic confirmation.
-
Patients
20,000+
enrolled
-
Sites
21
global centers
-
Outcomes
100%
of patients included in analysis had genetic confirmation
-
>99%
combined sensitivity for trisomies (T21, T18, T13)
-
83%
clinical sensitivity for 22q11.2 deletions (0.5 Mb+ deletions)
-
>95%
positive predictive value (PPV) for trisomy 21
-
ZERO
fetal sex errors in validation studies
What is NIPT and who is it for?
During pregnancy, small fragments of DNA released by the placenta enter the mother's bloodstream. NIPT analyses this cell-free DNA to estimate the likelihood of a numerical or structural difference in certain chromosomes of the baby.
The test uses a standard blood sample taken from the mother's arm. Because no needle enters the womb, it carries no risk of miscarriage. The Panorama™ test can be performed from week 9 of pregnancy.
Doctors often recommend NIPT in situations such as advanced maternal age, a high-risk result on combined or triple screening, suspicious ultrasound findings, or a family history of chromosomal conditions. Expectant mothers without risk factors may also choose the test after discussing it with their doctor.
This is a screening test, not a diagnostic test.
An NIPT result expresses a likelihood. If a high risk is identified, diagnostic tests such as chorionic villus sampling (CVS) or amniocentesis are required for a definitive diagnosis. A low-risk result does not guarantee the absence of all genetic conditions. Always make decisions about your pregnancy together with your doctor and a genetic counsellor.
Conditions Screened For
Panorama™ screens for common genetic conditions that are caused by extra or missing chromosomes in the baby’s DNA. Because Panorama™ uses a unique technology to distinguish between the pregnant person’s and the baby’s DNA, it is the only NIPT that tests for triploidy. Some conditions, such as Down syndrome, are caused by extra copies of a specific chromosome. Others, such as microdeletions, occur when a chromosome is missing a small piece of genetic information.
Trisomies
Trisomy 21 (Down syndrome)
Babies with Down syndrome have three copies of chromosome 21 and have intellectual disabilities that range from mild to severe. Children with Down syndrome will need extra medical care depending on the child’s specific health problems. Early intervention has allowed many individuals with Down syndrome to lead healthy and productive lives. The presence of medical conditions, like heart defects, can affect the lifespan in these children and adults; however, most individuals with Down syndrome will live into their 60s. Miscarriage occurs in about 30% of pregnancies with Down syndrome while overall about 1 in 700 babies are born with Down syndrome.
Trisomy 18 (Edwards syndrome)
Babies with trisomy 18 have three copies of chromosome 18 and have severe intellectual disabilities and birth defects typically involving the heart, brain, and kidneys. Babies with trisomy 18 can also have visible birth defects such as an opening in the lip (cleft lip) with or without an opening in the roof of the mouth (cleft palate), a small head, clubbed feet, underdeveloped fingers and toes, and a small jaw. Unfortunately, most pregnancies with trisomy 18 will miscarry. If born alive, most affected babies with trisomy 18 will pass away within the first few weeks of life. About 10 percent survive to their first birthday. Trisomy 18 occurs in approximately 1 in 3,000 live births.
Trisomy 13 (Patau syndrome)
Babies with trisomy 13 have three copies of chromosome 13 and have severe intellectual disabilities. They often have birth defects involving the heart, brain, and kidneys. Visible abnormalities include extra fingers and/or toes or an opening in the lip, with or without an opening in the palate. Given the severe disabilities, most pregnancies affected by trisomy 13 will miscarry. If born alive, most affected babies with trisomy 13 will pass away within the first few weeks of life. About 10 percent survive to their first birthday. Trisomy 13 occurs in approximately 1 in 5,000 live births.
Sex chromosome aneuploidies*
Monosomy X (Turner syndrome)
Babies with monosomy X are biological females who have one X chromosome instead of two. Unfortunately, a high proportion of pregnancies with monosomy X will result in a miscarriage in the first or second trimester of pregnancy. Babies with monosomy X that make it to term may have heart defects, learning difficulties, and infertility. In most cases, babies with monosomy X will need extra medical care including hormone therapy at various stages of life.
XXY syndrome (Klinefelter syndrome)
Babies with XXY syndrome have two X chromosomes and one Y chromosome (XXY). This condition can be associated with learning difficulties and behavioral problems. People with Klinefelter syndrome might be infertile. About 1 in 500 biological males will be born with Klinefelter syndrome.
Triple X syndrome
Babies with Triple X syndrome have three X chromosomes (XXX). Children with this condition could be taller than average and might experience learning difficulties or behavioral problems. Approximately 1 in 800 biological females will be born with three X chromosomes.
XYY syndrome (Jacobs syndrome)
Babies with XYY syndrome have one X chromosome and two Y chromosomes (XYY). Most babies with XYY syndrome do not have any birth defects. Children with XYY could be taller than average and have an increased chance for learning, speech, and behavioral problems. Approximately 1 in 1,000 biological males will be born with one X chromosome and two Y chromosomes.
Microdeletions*
22q11.2 deletion syndrome
22q11.2 deletion syndrome, also called DiGeorge syndrome or Velo-Cardio-Facial syndrome (VCFS), is caused by a missing piece of chromosome number 22. About one in every 2,000 babies is born with 22q11.2 deletion syndrome. The majority of children with this disorder have heart defects, immune system problems, and specific facial features. Most children with 22q11.2 deletion syndrome have mild-to-moderate intellectual disability and speech delays; some will also have low calcium levels, kidney problems, feeding problems, and/or seizures. About one in five children with 22q11.2 deletion syndrome have autism spectrum disorder; 1 in 4 adults with 22q11.2 deletion syndrome have a psychiatric illness, like schizophrenia.
Prader-Willi syndrome†
Prader-Willi syndrome occurs when either a small piece of chromosome 15 is missing or when both copies of chromosome 15 come from the same parent (called uniparental disomy, or UPD). Babies with Prader-Willi syndrome have low muscle tone and problems with growth and feeding. Children with Prader-Willi syndrome have delayed milestones, short stature, rapid weight gain leading to obesity, and intellectual disability. About 1 in 10,000 babies are born with Prader-Willi syndrome.
Angelman syndrome†
Angelman syndrome happens when either a small piece of chromosome 15 is missing, or when both copies of chromosome 15 come from the same parent (called uniparental disomy, or UPD). About 1 in 12,000 babies are born with Angelman syndrome. Babies and children with Angelman syndrome have severe intellectual disability, delayed milestones, seizures, and problems with balance and walking.
1p36 deletion syndrome
1p36 deletion syndrome, also referred to as Monosomy 1p36 syndrome, is caused by a missing piece of chromosome 1. Children with 1p36 deletion syndrome have intellectual disabilities. Most have heart defects and weak muscle tone. About half of affected individuals have seizures (epilepsy), behavioral problems, and hearing loss. Some children with 1p36 deletion syndrome also have vision problems or additional birth defects of other organs. About 1 in 5,000 newborn babies has 1p36 deletion syndrome.
Cri-du-chat syndrome
A missing piece of chromosome 5 causes Cri-du-chat syndrome, also called 5p- (5p minus) syndrome. The name “Cri-du-chat” was given to this syndrome due to the high-pitched, cat-like cry that babies with this syndrome often make. Babies with Cri-du-chat syndrome typically have low birth weight, a small head size, and weak muscle tone. Feeding and breathing problems are common in infancy. Children with this disorder have moderate-to-severe intellectual disability, including speech and language delays. They may also have heart defects, growth delays, behavior problems, and some have curvature of the spine (scoliosis). About one in every 20,000 babies is born with Cri-du-chat syndrome.
Triploidy*
The only NIPT that tests for triploidy
Babies with triploidy have a complete extra set of chromosomes for a total of 69 chromosomes instead of the usual 46. At 10 weeks gestation, one in 1,000 pregnancies is affected by triploidy. It is extremely rare for these pregnancies to reach term as they typically spontaneously miscarry early in pregnancy. Those few liveborns usually pass away within days of delivery due to heart, brain, and kidney problems. Babies with triploidy also often have birth defects affecting the extremities and face.
Carrying a baby with triploidy can increase a mother’s risk for a variety of conditions: pre-eclampsia (which can lead to seizures) and excessive bleeding after delivery. In rare instances, triploid pregnancies can persist and progress to a type of cancer called choriocarcinoma. Knowing about triploidy allows the physician to monitor the health of the mother appropriately.
* Not available for egg-donor or gestational carrier pregnancies or in cases of dizygotic (non-identical) twins. Triploidy and microdeletions, except for 22q11.2 deletions, are not available for monozygotic (identical) twins.
† This test has been validated on full region deletions of Prader-Willi syndrome/Angelman syndrome (PWS/AS) only and might be unable to detect smaller deletions. It has not been validated for other molecular mechanisms which could cause PWS/AS, such as uniparental disomy (UPD) or methylation.
Source: ACOG Practice Bulletin 226. Obstet Gynecol. 2020 Oct;136(4):859-867.
Why Panorama™?
The value of a screening test depends on laboratory quality, accurate reporting and a clear explanation of the result.
-
Advanced technology
Cell-free DNA is analysed using advanced sequencing and bioinformatics.
-
Validated performance
Sensitivity and specificity are documented in published clinical validation studies.
-
Fast results
Reports are issued on average within 10 working days of the sample reaching the laboratory.
-
Genetic counselling
Access to genetic counsellors before and after your result, for any questions or concerns.
-
Data security
Your personal and genetic data are processed and stored in line with applicable data protection law, including the GDPR.
-
Coordination with your doctor
The report is sent to the requesting doctor, with a direct line of communication between the doctor and our team.
Panorama™ for your pregnancy
Panorama™, the most ordered NIPT, can assess conditions that can affect your baby’s health by doing a simple blood draw on you. A pregnant person’s blood contains DNA from them and also from their baby’s placenta. Panorama™ NIPT is a blood test performed during pregnancy that looks at the placental DNA to see if your baby has a high or low chance of having certain chromosomal conditions that could affect its health, along with providing your baby’s sex. Panorama™ delivers a personalized risk report to you and your clinician.
Understanding your results
Panorama™ offers a personalized report, which indicates whether your baby has a high or low chance for developing certain genetic conditions. Panorama™ NIPT results are available within 10 working days from the time your sample is received at the laboratory. Learn more about SNP-based NIPT on our FAQs page.
Your report could state the following:
-
Low Risk
A low risk result means that the chance that your baby has one of the conditions tested by Panorama™ is very unlikely but not zero — less than 1 in 10,000 for most conditions.
-
High Risk
Panorama™ is a screening test, which means that this test does not make a final diagnosis. A high risk result means that your pregnancy has a higher chance of having a specific genetic condition. However, you cannot know for sure if your baby has that condition based on screening results alone.
…See more
If you receive a high risk Panorama™ result, speak with your healthcare provider (HCP) to discuss which next steps you could decide to pursue, such as genetic counseling, detailed ultrasound, and the option of diagnostic testing.
All medical decisions should be made after discussion with your HCP regarding diagnostic testing during the pregnancy, like chorionic villus sampling (CVS) or amniocentesis, or testing the baby after birth.
-
No Result
About 1 in 65 tests could receive a nonreportable result. You should speak with your HCP about these result types and whether you should consider having a second blood draw to do the test again. There is also a small chance that Panorama™ will have a result relating to your genetics or your physical health.
How it works
-
Step 1
Doctor consultation
Your doctor assesses whether the test is right for you and completes the request form.
-
Step 2
Blood draw
A single tube of blood is taken from your arm at a partner centre and sent to the laboratory.
-
Step 3
Laboratory analysis
Cell-free DNA is isolated, sequenced and evaluated using bioinformatics methods.
-
Step 4
Results and counselling
The report is sent to your doctor; if needed, genetic counsellors review the result with you.
Conditions screened
Coverage depends on the panel selected. Under each heading you will find a short description of the condition.
Trisomies
Trisomy 21 Down syndrome
Three copies of chromosome 21 instead of two. It affects learning and development and increases the likelihood of certain heart and digestive anomalies.
Trisomy 18 Edwards syndrome
Caused by an extra copy of chromosome 18. It is associated with serious developmental problems affecting several organ systems, and many pregnancies do not reach term.
Trisomy 13 Patau syndrome
Three copies of chromosome 13. It involves severe structural anomalies affecting the brain, heart and face.
Sex chromosomes
Monosomy X Turner syndrome (45,X)
A missing X chromosome in girls. It may be associated with short stature, reduced ovarian function and some heart or kidney differences.
XXY Klinefelter syndrome (47,XXY)
An extra X chromosome in boys. Features are often mild; hormonal differences in puberty and later fertility problems may occur.
XXX Triple X (47,XXX)
An extra X chromosome in girls. Many people have no noticeable features; some children may need support with language and learning.
XYY 47,XYY
An extra Y chromosome in boys. It often goes unnoticed; differences in height and speech development may occur.
Microdeletions
22q11.2 deletion DiGeorge syndrome
A small missing segment of chromosome 22. It may be associated with heart defects, palate differences, and immune and calcium regulation problems.
1p36 deletion 1p36 deletion syndrome
A missing segment at the end of the short arm of chromosome 1. It may be associated with developmental delay, low muscle tone and seizures.
5p deletion Cri-du-chat syndrome
A missing segment of the short arm of chromosome 5. It is characterised by a high-pitched cry in infancy and developmental delay.
15q11-q13 deletion Angelman / Prader-Willi syndromes
A deletion in the same region can lead to two different conditions depending on whether it is inherited from the mother or the father. Which one applies is determined by further diagnostic testing.
Other
Triploidy 69 chromosomes
Three sets of chromosomes instead of two. The pregnancy usually cannot continue and may require close monitoring of the mother's health. Scope: X.
Fetal sex Optional
Sex chromosome information is reported only within applicable legal regulations and at the doctor's request: X.
This list reflects the current scope of the test: X. The microdeletion panel is optional; screening performance is more limited than for trisomies.
The only SNP-based NIPT
-
Only Panorama™
Panorama™ is the only SNP-based NIPT able to distinguish between the pregnant person’s and fetal (placenta) DNA to deliver unique, clinically validated capabilities.
-
Validated with clinical rigor
Demonstrated performance in a real-world population in the largest prospective NIPT study. 99% sensitivity, >99% specificity, and 95% positive predictive value (PPV) for trisomy 21. Panorama™ had zero fetal sex errors in validation studies.
-
Continuously innovating
Enhancing test capabilities for 10+ years
Detects conditions that other tests cannot, including maternal X mosaicism, triploidy and reporting results for the viable twin in a vanishing twin pregnancy.
Complete Test Specifications for Singleton, Egg Donor, Gestational Carrier, and Monozygotic (Identical) Twins
Definition of performance terms
Sensitivity is the ability to correctly identify a truly high risk case as high risk. For example, in a group of Trisomy 21 cases, Panorama™ will correctly identify more than 99% of those cases.
Specificity is the ability to correctly identify an unaffected case as low risk.
Positive Predictive Value (PPV) is the likelihood the result says high risk and the fetus is actually affected. For example, when Panorama™ shows a high risk result for Trisomy 21, there is a 95% chance that the fetus is affected by Trisomy 21. In other words, 5% of the time, you could get a high risk result when the fetus is not affected by Trisomy 21.
Negative Predictive Value (NPV) is the likelihood the result says low risk and the fetus is truly not affected.
Show table
| Condition | Sensitivity (95% CI) | Specificity (95% CI) | PPV | NPV |
|---|---|---|---|---|
| Trisomy 21 | 99.0% (CI 97.1-100) | >99% (CI 99.93-99.99) | 95% | >99.99%‡ |
| Trisomy 18 | 94.1% (CI 82.9-100) | >99% (CI 99.96-100) | 91% | >99.99%‡ |
| Trisomy 13 | >99% (CI 73.5-100) | >99% (CI 99.96-100) | 68% | >99.99%‡ |
| Monosomy X* | 83.3% (CI 53.5-100) | >99% (CI 99.7-100) | 78% | >99.99%‡ |
| Triploidy* | >99% (CI 66.4-100) | >99% (CI 99.5-100) | 7.5% | >99.99%‡ |
| XXX, XXY, XYY* | 70.4% (CI 53.2-87.5) | 99.9% (CI 99.90-100) | 83% | 99.92%‡ |
| 22q11.2 deletion syndrome* | 83.3% (CI 51.6-97.9) | >99% (CI 99.91-99.98) | 53% | 99.9%§ (CI 99.9-100) |
| 1p36 deletion syndrome* | >99% (CI 2.5-100) | >99% (CI 99.1-100) | 7-17%§ | 99.98-99.99%§ |
| Angelman syndrome*† | 95.5% (CI 77.2-99.9) | >99% (CI 99.1-100) | 10% | >99.99% |
| Cri-du-chat syndrome* | >99% (CI 85.8-100) | >99% (CI 99.1-100) | 2-5%§ | >99.99% |
| Prader-Willi syndrome*† | 93.8% (CI 69.8-99.8) | >99% (CI 99.1-100) | 5% | >99.99% |
| Fetal sex: female | >99.9% (CI 99.4-100) | >99.9% (CI 99.5-100) | – | – |
| Fetal sex: male | >99.9% (CI 99.5-100) | >99.9% (CI 99.4-100) | – | – |
Test Specifications for Dizygotic (Non-identical) Twins
Show table
| Condition | PPV |
|---|---|
| Trisomy 21 | 88% |
| Trisomy 18 | 70% |
| Trisomy 13 | 67% |
More than 10% of dizygotic pregnancies may not receive a result due to low fetal fractions.
* Not available for egg-donor or gestational carrier pregnancies or in cases of dizygotic (non-identical) twins. Triploidy and microdeletions, except for 22q11.2 deletions, are not available for monozygotic (identical) twins.
† This test has been validated on full region deletions of Prader-Willi syndrome/Angelman syndrome (PWS/AS) only and might be unable to detect smaller deletions. It has not been validated for other molecular mechanisms which could cause PWS/AS, such as uniparental disomy (UPD) or methylation.
‡ Ongoing clinical follow-up is performed to ensure the NPV does not fall below the quoted value, but follow-up is not obtained for all low risk calls.
§ Dependent upon fetal fraction (FF). For 22q11.2 deletion syndrome, only the paternal allele is evaluated at FF ≤ 6.5%. For 1p36 deletion syndrome and Cri-du-chat syndrome, only the paternal allele is evaluated at FF < 7%. For Angelman syndrome, no risk assessment is reported at FF < 7%. For Prader-Willi syndrome, no risk assessment is reported at FF ≤ 2.8%.
Clinical validation
Study
X1
The test's performance has been evaluated in clinical validation studies comparing it with independent diagnostic tests (karyotyping, microarray, etc.). Study design, participant characteristics and limitations are described in detail in the publication.
Read the publication-
X
pregnancies enrolled
-
X
clinical centres
-
X
Trisomy 21 sensitivity
-
X
Trisomy 21 specificity
- 1. X
Video coming soon:
Featured
Webinar for physicians: interpreting NIPT results
An information session on reading NIPT reports, samples with low fetal fraction and next steps after a high-risk result.
Duration: X
Frequently asked questions
Can't find the answer you need? Write to us.
Patient FAQ
Prenatal screen overview
Who should have the Panorama™ prenatal screen?
The Panorama™ prenatal screen is designed for women of any age and ethnicity who are at least 9 weeks pregnant. It cannot currently be used by women carrying three or more babies (triplets and above), women who have used an egg donor or surrogate carrying more than one baby (twins or triplets), or those who have received a bone marrow transplant.
When should I have the Panorama™ prenatal screen?
Panorama™ can be performed as early as 9 weeks into the pregnancy.
What are the benefits of having the Panorama™ prenatal screen?
As early as 9 weeks into your pregnancy, a simple blood draw can tell you if your baby is at higher risk for having Down syndrome and other common genetic conditions, as well as the sex of your baby. Noninvasive and highly accurate, Panorama™ identifies more than 99% of pregnancies affected with Down syndrome and has the lowest reported false positive rate of any prenatal screening test for the commonly screened chromosomal abnormalities: trisomy 21, trisomy 18 and trisomy 13.
Who can I talk to about my Panorama™ prenatal screen results?
Typically, you will receive your Panorama™ screen results from the healthcare provider who ordered the test. If you have a specific question about your results, contact our team using the form on this page and we will arrange a conversation with a genetic counsellor.
Panorama™ prenatal screen logistics
How do I request the Panorama™ prenatal screen?
If you are interested in the Panorama™ test, you can start a conversation about noninvasive prenatal testing with your doctor at your first prenatal visit. You can also fill in the request form on this page and our team will contact you.
What type of sample do I need to submit?
Panorama™ only requires a simple blood draw from the pregnant patient.
What should I be screened for?
Panorama™ is able to determine the likelihood that the pregnancy could be affected with chromosome abnormalities including Down syndrome (trisomy 21), trisomy 18, trisomy 13, monosomy X and triploidy. Your doctor may also recommend additional chromosomal conditions (microdeletions) be screened for using Panorama™. Microdeletion conditions on the Panorama™ extended panel include 22q11.2 deletion syndrome, 1p36 deletion, Cri-du-chat syndrome, Prader-Willi syndrome and Angelman syndrome. While it is not the sole purpose of the test, the sex of the baby can also be screened for using Panorama™.
Results & reports
How will I know when my results are available?
You will receive your results from your doctor’s office. They may tell you the results over the phone or ask you to come into their office.
How are the results reported?
When you get your Panorama™ results, your report may state the following:
Low Risk: A Low Risk result indicates that it is unlikely that your baby is affected by one of the conditions on the Panorama™ prenatal screen.
High Risk: A High Risk result does not mean the baby is affected; rather, it indicates a higher than average chance that the baby has a chromosome abnormality. Your healthcare provider may recommend that you speak with a genetic counsellor and/or maternal-fetal medicine specialist. You may be offered invasive diagnostic testing such as amniocentesis or chorionic villus sampling (CVS). No irreversible pregnancy decisions should ever be made based on a Panorama™ result alone.
No Result: In a small percentage of cases, Panorama™ may not be able to obtain sufficient information from your blood sample to determine an accurate result. If this occurs, a second blood sample may be requested.
Costs & billing
What is the cost of the Panorama™ prenatal screen?
The cost of Panorama™ varies with the prenatal screening panel selected. For current prices, contact us using the form on this page.
Does my insurance cover the Panorama™ prenatal screen?
Insurance coverage for Panorama™ depends on your health insurance plan and coverage benefits. Contact us to find out whether your insurer covers the test.
I didn’t find the answer I was looking for…
If you have questions about the Panorama™ prenatal screen or its cost, contact our team using the form on this page.
If you have personal healthcare related questions (e.g. family history, ultrasound findings, healthcare decision making) or would like to take the Panorama™ prenatal screen, we encourage you to speak to your healthcare provider.
Provider FAQ
Clinical support
How can I contact a genetic counsellor if I have questions about a patient result?
Contact our team using the form or contact details on this page and we will put you in touch with a genetic counsellor who can answer your questions about the Panorama™ prenatal screen.
Is assistance available to patients who have high-risk Panorama™ results?
Yes. Patients can have an information session with a genetic counsellor to discuss their Panorama™ screening results. Your patients can contact our team using the form on this page to arrange a session at a time that is convenient for them.
Ordering & logistics
How do I begin offering Panorama™ in my practice?
Fill in the form on this page, selecting “Physician” or “Institution / Hospital”, and our team will contact you to set up an account.
How do I order more kits?
Tell your local Pangea Genomics representative, or write to us using the form on this page and tell us how many kits you want and when you would like them.
How do I complete the requisition form?
Please complete the patient information on the upper left side and the clinician information on the upper right side. Select the Panorama™ panel and the fetal sex option from the “Screening Requested” section by checking the appropriate box. When completing the requisition form, it is important to correctly mark whether your patient is carrying a singleton or twins, or an egg donor/surrogate pregnancy, to ensure that the sample is run on the correct testing platform. Missing information on the requisition form may cause a delay in turnaround time for results.
Sample requirements & shipping
What are the sample requirements for Panorama™?
Panorama™ requires two cell-free DNA Streck tubes, each filled with at least 10 mL of the pregnant patient’s blood. A straight needle is recommended for the blood draw. Collected samples should be shipped to the laboratory on the same day as the blood draw.
How do I store collected samples before shipping?
Collected samples should be stored between 6-37°C (43-98°F). Do not refrigerate or freeze collected samples – they should be stored at room temperature.
Where and how should Panorama™ kits be stored?
Samples can be stored briefly before shipping between 6-37°C (43-98°F), but then samples should be shipped so that they arrive at the laboratory no later than 7 days after sample collection. The expiration date is listed on the side of your kit beneath the test name. If your kits are expired, please reach out to your Pangea Genomics representative.
Results & reporting
What does a Panorama™ report look like?
Contact us using the form on this page and we will send you a Panorama™ sample report.
Test request and contact
Fill in the form and our team will contact you as soon as possible. Physicians and institutions can also use this form for partnership enquiries.